Literature DB >> 23769662

Early PROMs following total knee arthroplasty--functional outcome dependent on patella resurfacing.

Paul N Baker1, Timothy Petheram2, Daniel Dowen2, Simon S Jameson3, Peter J Avery4, Mike R Reed5, David J Deehan6.   

Abstract

Patella resurfacing during primary total knee arthroplasty (TKA) remains controversial. Variation in published results for patella resurfacing may potentially be explained by differences in design between TKA brands. We interrogated NJR-PROMs data to ascertain whether there is an early functional benefit to resurfacing the patella, both overall and for each of the five most popular primary knee designs through use of the Oxford Knee Score. A total of 8103 resurfaced TKAs and 15,290 nonresurfaced TKAs were studied. There was a large variation in the proportion of knees undergoing patella resurfacing by brand (Nexgen=16% versus Triathlon=52%). Patellar resurfacing did not significantly influence the magnitude of improvement in overall knee function or anterior knee-specific function irrespective of TKA brand or for cruciate retaining versus sacrificing designs.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  PROMs; patella resurfacing; total knee arthroplasty

Mesh:

Year:  2013        PMID: 23769662     DOI: 10.1016/j.arth.2013.05.001

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  3 in total

1.  Effect of patellar thickness on early results of total knee replacement with patellar resurfacing.

Authors:  Qunn Jid Lee; Sze Tsun Yeung; Yiu Chung Wong; Yuk Leung Wai
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2014-08-22       Impact factor: 4.342

2.  Patellar resurfacing after endoprosthetic replacement for primary or secondary bone tumors.

Authors:  Alexander D Liddle
Journal:  Ann Transl Med       Date:  2016-11

Review 3.  Effect of patella resurfacing on functional outcome and revision rate in primary total knee arthroplasty (Review).

Authors:  Sorin Radu Fleaca; Cosmin Ioan Mohor; Horatiu Dura; Radu Chicea; Calin Mohor; Adrian Boicean; Mihai Dan Roman
Journal:  Exp Ther Med       Date:  2021-12-01       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.